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Abstract
Background
A recent Cochrane review compared laparoscopic versus open distal pancreatectomy for peo-
ple with for cancers of the body and tail of the pancreas and found that laparoscopic distal pan-
createctomy may reduce the length of hospital stay. We compared the cost-effectiveness of
laparoscopic distal pancreatectomy versus open distal pancreatectomy for pancreatic cancer.
Method
Model based cost-utility analysis estimating mean costs and quality-adjusted life years
(QALYs) per patient from the perspective of the UK National Health Service. A decision tree
model was constructed using probabilities, outcomes and cost data from published sources.
A time horizon of 5 years was used. One-way and probabilistic sensitivity analyses were
undertaken.
Results
The probabilistic sensitivity analysis showed that the incremental net monetary benefit was
positive (£3,708.58 (95% confidence intervals (CI) -£9,473.62 to £16,115.69) but the 95%
CI includes zero, indicating that there is significant uncertainty about the cost-effectiveness
of laparoscopic distal pancreatectomy versus open distal pancreatectomy. The probability
laparoscopic distal pancreatectomy was cost-effective compared to open distal pancreatec-
tomy for pancreatic cancer was between 70% and 80% at the willingness-to-pay thresholds
generally used in England (£20,000 to £30,000 per QALY gained). Results were sensitive to
the survival proportions and the operating time.
Conclusions
There is considerable uncertainty about whether laparoscopic distal pancreatectomy is cost-
effective compared to open distal pancreatectomy for pancreatic cancer in the NHS setting.
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Background
Pancreatic cancer is the tenth most common cancer in the United States, the fifth most com-
mon cause of cancer-related mortality in the East and the fourth most common cause of can-
cer-related mortality in the West [1–3]. Adenocarcinoma of the pancreas is the most common
malignancy of the exocrine pancreas. In 2012, 338,000 people were newly diagnosed with pan-
creatic cancer globally, and 330,000 deaths were the result of pancreatic cancer [4]. Surgical
resection with adjuvant chemotherapy remains the only treatment with the potential for long-
term survival. However, about half the people have metastatic disease at presentation, and
one-third have locally advanced unresectable disease, leaving only about 10% to 20% of people
suitable for resection [5]. Surgical resection is either pancreatoduodenectomy for cancers of
the head of the pancreas or distal pancreatectomy for cancers of the body and tail of the pan-
creas [6]. Approximately, 20% of 30% of pancreatic resections are distal pancreatectomies [7,
8]. In open distal pancreatectomy, surgical access to the abdominal cavity (and hence the pan-
creas) is attained by upper midline incision, bilateral subcostal incision (roof-top or Chevron
incision) or transverse abdominal incision [9]. In laparoscopic distal pancreatectomy, surgical
access to the abdominal cavity (and hence the pancreas) is typically attained by 4 to 6 small
ports (holes) of about 5 to 12 mm each through which laparoscopic instruments can be in-
serted after the abdomen is distended using carbon dioxide pneumoperitoneum [9]. After
resection of the body and tail of the pancreas, the cut surface of the pancreatic remnant (pan-
creatic stump) is usually closed with staples or sutures [10]. A recent Cochrane review com-
pared laparoscopic distal pancreatectomy with open distal pancreatectomy for pancreatic
cancer [11]. This review found that the hospital stay may be shorter with laparoscopic distal
pancreatectomy compared to open distal pancreatectomy [11]. There was no evidence of dif-
ferences in short-term term or long-term mortality, complications, recurrence, lymph node
retrieval or cancer-free resection margins between laparoscopic and open distal pancreatec-
tomy. The aim of this study is to perform a model-based cost-utility analysis of laparoscopic
versus open distal pancreatectomy for pancreatic cancer.
Methods
A model-based cost-utility analysis estimating mean costs and quality-adjusted life years
(QALYs) per patient was performed. We compared laparoscopic versus open distal pancrea-
tectomy. The time horizon was 5 years and an NHS perspective to measure costs was used. A
time horizon of 5 years was judged to be appropriate because cancer-related mortality is likely
to occur during this period. Any impact on costs and health-related quality of life is likely to
be captured or indicated within this period. Discounting of costs and utilities was performed
at the rate of 3.5% per annum [12]. A decision tree model was constructed (Fig 1). A patient
undergoing distal pancreatectomy for cancer of the body or tail of the pancreas may have the
operation done by laparoscopic or open procedure. A proportion of patients undergoing lapa-
roscopic distal pancreatectomy may require conversion to open procedure. A proportion of
patients in whom laparoscopic distal pancreatectomy was completed successfully will develop
complications, a proportion of whom may die within 90 days. Those who are alive at 90 days
may die between 90 days and 1 year; a proportion of people who are alive at 1 year may die
between 1 year and 2 years; and so on. The decision tree pathways in the people who required
conversion from laparoscopic distal pancreatectomy to open procedure and those who had
open surgery at the outset were identical to those in whom the procedure was completed
laparoscopically.
The decision tree was populated with probabilities, outcomes, and cost data from published
sources whenever possible. Literature searches were undertaken of articles published up to
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March 2017 that reported on utilities in patients with pancreatic cancer and patients undergo-
ing pancreatectomy. We also reviewed the Cost-Effectiveness Analysis Registry (CEA) at Tufts
University for information on quality of life [13]. Costs were obtained from the National
Schedule of Reference costs (2014–2015) [14]. We assumed that the people who died in each
period did so at a constant rate during the period. We assumed that patients who died received
supportive care in the last 3 months prior to their death. When no data were available from
published sources, a range of values were used in the model. For example, there was paucity of
data on the impact of complications on health-related quality of life after distal pancreatec-
tomy. There is no information available on the impact of complications on the quality of life
Fig 1. Decision tree. Decision tree showing the decision tree pathways in the people with body and tail of pancreatic cancer who underwent distal
pancreatectomy.
https://doi.org/10.1371/journal.pone.0189631.g001
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after pancreatic surgery. Based on small studies not sufficiently powered to identify differences
in liver and gynaecological surgery, there was no evidence of difference in health-related qual-
ity of life between complicated and uncomplicated surgery [15, 16]. However, this is counter-
intuitive and therefore we used a hypothetical 20% relative decrease in short-term HRQoL
because of surgical complications based on the opinion of clinical experts; this was varied in
sensitivity analysis. Similarly, there was no data on the health-related quality of life in the first
90 days after laparoscopic distal pancreatectomy. We used a hypothetical 10% relative increase
in short-term HRQoL in laparoscopic versus open distal pancreatectomy. We performed a sce-
nario analysis where we assumed that there was no difference in short-term HRQoL in laparo-
scopic versus open distal pancreatectomy.
Costs of surgery
Since the costs of laparoscopic pancreatic surgery was not available from the NHS reference
costs, we estimated the costs based on the operating time and hospital stay from the studies
included in the Cochrane review [11] and based on local estimates and the bed stay costs of
NHS reference costs of ‘Complex Open, Hepatobiliary or Pancreatic Procedures, with CC
Score 0 to 2’ HRG code: GA04D. For complicated surgery, we included a relative increase of
30% in costs based on the relative increase in costs between GA04C (CC score 3+) and GA04D
(CC score 0 to 2) of ‘Complex Open, Hepatobiliary or Pancreatic Procedures’ of NHS refer-
ence costs. In addition, the costs for staplers were included for about 90% of patients in whom
the procedure was started laparoscopically (i.e. those in whom the procedure was started and
completed laparoscopically and in those whom the procedure was converted from laparo-
scopic to open procedure) and about 70% of patients in whom the procedure was started as
open procedure. We performed a sensitivity analysis where we assumed that 100% of laparo-
scopic distal pancreatectomy was performed using staplers and all of the open distal pancrea-
tectomy was performed using hand-sewn stump closure. We estimated that one stapler will be
used in 90% of the patients and two staplers will be used in 10% of the patients for distal pan-
createctomy. We did not include any capital costs for laparoscopic equipment as we antici-
pated that all centres performing distal pancreatectomy have laparoscopic equipment for
carrying out other procedures such as laparoscopic cholecystectomy.
The inputs used in the decision tree model and the source of these input is shown in Table 1.
Measuring cost-effectiveness
Cost-effectiveness was measured using net monetary benefits (NMBs). For each treatment, the
NMB was calculated as the mean QALYs per patient accruing to that treatment multiplied by
decision-makers’ maximum willingness to pay for a QALY (also referred to as the cost-effec-
tiveness threshold), minus the mean cost per patient for the treatment. In the UK, the lower
and upper limit of the maximum willingness to pay for a QALY are £20 000 (approximately €
22 350 and 26 250 USD) and £30 000 (approximately € 33 500 and 39 400 USD) respectively
[12]. NMBs were calculated using the base case parameter values shown in Table 1; these are
deterministic results because they do not depend on chance. The option with the highest NMB
represents best value for money. The NMB for laparoscopic surgery minus the NMB for open
surgery is the incremental NMB. If the incremental NMB is positive (negative) then laparo-
scopic surgery (open surgery) represents better value for money.
A probabilistic sensitivity analysis (PSA) was also undertaken [12]. The PSA involves
Monte Carlo simulation and takes variability of all selected inputs into account simulta-
neously. Distributions described in the tables were assigned to parameters (Table 1) to reflect
the uncertainty with each parameter value.
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Table 1. Parameters used in the model and their source.
Parameter Type of
distribution
Mean (gamma or
continuous), lower limit
(uniform), number with
event (dichotomous)
Standard deviation
(gamma or continuous),
upper limit (uniform),
number without event
(dichotomous)
Point
estimate
Source / Notes
Probabilities
90-day mortality
(laparoscopic distal
pancreatectomy)
Beta 1 328 0.3% Data from Cochrane review [11]
Complications
(laparoscopic distal
pancreatectomy)
Beta 33 76 30.3% Data from Cochrane review [11]
Conversion (laparoscopic
distal pancreatectomy)
Beta 70 278 20.1% Data from Cochrane review [11]
1-year mortality
(laparoscopic distal
pancreatectomy)
Beta 21 83 20.2% Data from Cochrane review [11]
2-year mortality
(laparoscopic distal
pancreatectomy)
Beta 44 60 42.3% Data from Cochrane review [11]
3-year mortality
(laparoscopic distal
pancreatectomy)
Beta 64 40 61.5% Data from Cochrane review [11]
4-year mortality
(laparoscopic distal
pancreatectomy)
Beta 74 19 79.6% Data from Cochrane review [11]
5-year mortality
(laparoscopic distal
pancreatectomy)
Beta 76 17 81.7% Data from Cochrane review [11]
90-day mortality (open
pancreatectomy)
Beta 11 1111 1.0% Data from Cochrane review [11]
Complications (open distal
pancreatectomy)
Beta 45 92 32.8% Data from Cochrane review [11]
1-year mortality (open
distal pancreatectomy)
Beta 50 123 28.9% Data from Cochrane review [11]
2-year mortality (open
distal pancreatectomy)
Beta 84 89 48.6% Data from Cochrane review [11]
3-year mortality (open
distal pancreatectomy)
Beta 110 63 63.6% Data from Cochrane review [11]
4-year mortality (open
distal pancreatectomy)
Beta 124 26 82.7% Data from Cochrane review [11]
5-year mortality (open
distal pancreatectomy)
Beta 126 24 84.0% Data from Cochrane review [11]
Costs
Hospital stay (per day) Gamma £352.48 £195.24 £352.48 National schedule of reference
costs 2015 to 2016: the main
schedule GA04D (Complex Open,
Hepatobiliary or Pancreatic
Procedures, with CC Score 0 to 2)
(median and quartiles converted to
mean and standard deviation) [14]
Operating time (per
minute)
Uniform £17.00 £18.00 £17.50. Local estimate
Stapler Uniform £200.00 £300.00 £250.00 Local estimate
Proportion of patients in
whom stapler was used in
laparoscopic distal
pancreatectomy
Beta 90 10 90% Local estimate
(Continued )
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Table 1. (Continued)
Parameter Type of
distribution
Mean (gamma or
continuous), lower limit
(uniform), number with
event (dichotomous)
Standard deviation
(gamma or continuous),
upper limit (uniform),
number without event
(dichotomous)
Point
estimate
Source / Notes
Proportion of patients in
whom stapler was used in
open distal
pancreatectomy
Beta 70 30 70% Local estimate
Costs of distal
pancreatectomy
- - - - There is no estimate available for
laparoscopic or open distal
pancreatectomy. The costs of
pancreatectomy were based on the
hospital stay, operating time, and
the number of staplers used. In
addition, we used a 30% relative
increase in the costs related to
complicated procedures based on
the relative increase in costs of
GA04C (CC score 3+) versus
GA04D (CC score 0 to 2) of
‘Complex Open, Hepatobiliary or
Pancreatic Procedures’ of NHS
reference costs.
Health-related quality of life
Complicated laparoscopic
distal pancreatectomy—
first 3 months
Beta 0.2 0.8 20.0% Hypothetical relative 20% decrease
compared to uncomplicated distal
pancreatectomy
Uncomplicated
laparoscopic distal
pancreatectomy—first 3
months
Beta 0.1 0.9 10.0% Hypothetical 10% relative increase
because of laparoscopic surgery
Complicated open distal
pancreatectomy—first 3
months
Beta 0.2 0.8 20.0% Hypothetical 20% relative decrease
compared to uncomplicated distal
pancreatectomy
Uncomplicated open distal
pancreatectomy—first 3
months
Gamma 0.63 0.30 0.63 Ljungman et al [17].
Distal pancreatectomy
subsequent stable period
Gamma 0.69 0.33 0.69 Ljungman et al [17]
Supportive care Gamma 0.14 0.18 0.14 Tam et al [18]
Other parameters
Length of hospital stay
(laparoscopic
pancreatectomy) (days)
Gamma -2.43 11.67152474 -2.43 Data from Cochrane review [11]
Operating time
(laparoscopic
pancreatectomy) (minutes)
Gamma -18.46 292.733099 -18.46 Data from studies included in the
Cochrane review [11]
Length of hospital stay
(laparoscopic
pancreatectomy) (days)
Gamma -2.43 11.67152474 -2.43 Data from Cochrane review [11]
Operating time
(laparoscopic
pancreatectomy) (minutes)
Gamma -18.46 292.733099 -18.46 Data from studies included in the
Cochrane review [11]
Proportion of surgeries in
which one stapler was
used
Beta 0.9 0.1 0.9 Hypothetical
https://doi.org/10.1371/journal.pone.0189631.t001
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A random value from the corresponding distribution for each parameter was selected. This
generated an estimate of the mean cost and mean QALYs and the NMB associated with each
treatment. This was repeated 5000 times and the results for each simulation were noted. The
mean costs, QALYs and NMB for each treatment was calculated from the 5000 simulations;
these are probabilistic results because they depend on chance. The NMB was also calculated
for each of the 5000 simulations and the proportion of times each treatment had the highest
NMB was calculated for a range of values for the maximum willingness to pay for a QALY.
These were summarised graphically using cost-effectiveness acceptability curves. 95% confi-
dence intervals around the base case values were derived using the 2.5 and 97.5 percentiles cal-
culated from the PSA. In cases where standard errors were required for the PSA and these
were not reported in the sources used it was assumed the standard error was equal to the
mean.
For the deterministic univariate sensitivity analysis, each variable in the cost-effectiveness
model was varied one at a time. The results of the sensitivity analysis are represented in the tor-
nado diagram which reflects the variation in the NMB within the range of the lowest and high-
est value used for a parameter with all else equal. If the variation in the NMB includes 0, then
there is uncertainty in the cost-effectiveness due to the variation of the parameter.
Results
The results of deterministic analysis are shown in Table 2.
This shows that laparoscopic distal pancreatectomy results in decreased costs and increased
QALYs compared to open distal pancreatectomy, with a higher net monetary benefit. There-
fore, laparoscopic distal pancreatectomy dominates open distal pancreatectomy, and the incre-
mental NMB is positive.
The results of probabilistic sensitivity analysis are shown in Table 3.
The probabilistic sensitivity analysis shows that laparoscopic distal pancreatectomy results
in decreased costs (not statistically significant) and increased QALYs (not statistically signifi-
cant) compared to open distal pancreatectomy (i.e. laparoscopic distal pancreatectomy domi-
nates open distal pancreatectomy), with a significantly higher net monetary benefit. Again, the
incremental net monetary benefit is positive; however, the 95% confidence intervals include
zero.
The scatter plot showing the incremental cost per incremental quality adjusted life years
(QALY) per patient for a cohort of 5000 patients is shown in Fig 2. The scatter plot shows that
the points lie almost symmetrical about the X-axis, i.e. the costs were similar between laparo-
scopic and open distal pancreatectomy, but most points lie to the right of the Y-axis, i.e. lapa-
roscopic distal pancreatectomy was associated with increased QALYs.
We calculated data points to construct a cost-effectiveness acceptability curve, which
showed that the probability laparoscopic distal pancreatectomy was cost-effective compared to
Table 2. Results of deterministic analysis (per patient).
Treatment Costs QALYs Net monetary benefit*
£20,000 £30,000
Laparoscopic distal pancreatectomy £7,676 1.6472 £25,267.54 £41,739.31
Open distal pancreatectomy £8,539 1.4974 £21,409.10 £36,383.12
Incremental -£863 0.1498 £3,858.45 £5,356.20
* Calculated at willingness to pay thresholds of £20,000 and £30,000 per QALY gained.
QALY = quality adjusted life year.
https://doi.org/10.1371/journal.pone.0189631.t002
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open distal pancreatectomy was 70% to 80% at the willingness-to-pay thresholds generally
used in England (£20,000 to £30,000 per QALY gained) (Fig 3).
Table 3. Results of probabilistic sensitivity analysis (per patient).
Treatment Costs QALYs Net monetary benefit*
£20,000 £30,000
Laparoscopic distal
pancreatectomy
£7,675
(95% CI £1,947 to
£19,968)
1.6446
(95% CI 0.5998 to
3.3513)
£25,217.57
(95% CI £1,410.56 to
£60,672.87)
£41,663.68
(95% CI £8,750.01 to
£94,019.22)
Open distal pancreatectomy £8,556
(95% CI £1,762 to
£21,872)
1.4954
(95% CI 0.5487 to
3.0779)
£21,352.50
(95% CI -£1,768.51 to
£53,381.03)
£36,306.83
(95% CI £4,801.25 to
£83,318.20)
Incremental -£882
(95% CI -£12,494 to
£12,357)
0.1492
(95% CI 0.0003 to
0.4180)
£3,865.07
(95% CI -£9,641.19 to
£16,397.43)
£5,356.85
(95% CI -£8,678.12 to
£19,137.46)
* Calculated at willingness to pay thresholds of £20,000 and £30,000 per QALY gained.
QALY = quality adjusted life year.
https://doi.org/10.1371/journal.pone.0189631.t003
Fig 2. Scatter plot of incremental cost per incremental quality-adjusted life year. The scatter plot shows that the points lie almost symmetrical about
the X-axis, i.e. the costs were similar between laparoscopic and open distal pancreatectomy, but most points lie to the right of the Y-axis, i.e. laparoscopic
distal pancreatectomy was associated with increased quality-adjusted life years (QALYs).
https://doi.org/10.1371/journal.pone.0189631.g002
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Univariate sensitivity analysis
Using a cost-effectiveness threshold value of £20,000 per QALY gained, all else equal, laparo-
scopic distal pancreatectomy was cost-effective, as long as the probability of 90-day mortality
was<30%, 1-year mortality was<55%, 2-year mortality was <75%, 3-year mortality was
<95%, and the operating time was< 500 minutes in people who undergo laparoscopic distal
pancreatectomy. Laparoscopic distal pancreatectomy was also cost-effective at this threshold
all else equal if 2-year mortality was >20%, 3-year mortality was >35%, 4-year mortality was
>50%, and 5-year mortality was >30% in the open distal pancreatectomy group. Laparoscopic
distal pancreatectomy was cost-effective versus open distal pancreatectomy for all other values
for the different parameters. The tornado diagram shows that there is significant uncertainty
in the results, especially with regards to mortality (Fig 4).
Fig 3. Cost-effectiveness acceptability curve. The cost-effectiveness acceptability curve shows that the probability laparoscopic distal pancreatectomy
was cost-effective compared to open distal pancreatectomy was 70% to 80% at the willingness-to-pay thresholds generally used in England (£20,000 to
£30,000 per QALY gained).
https://doi.org/10.1371/journal.pone.0189631.g003
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Scenario analysis
Scenario analysis 1: Difference in the use of stapler between laparoscopic and open dis-
tal pancreatectomy. As indicated in Table 4, there was no change in the interpretation of the
results compared to the main analysis.
Fig 4. Univariate sensitivity analysis (Tornado diagram). The tornado diagram shows that there is significant uncertainty in the results, especially with
regards to mortality.
https://doi.org/10.1371/journal.pone.0189631.g004
Table 4. Results of probabilistic sensitivity analysis (per patient) (scenario analysis 1).
Treatment Costs QALYs Net monetary benefit*
£20,000 £30,000
Laparoscopic distal
pancreatectomy
£7,680
(95% CI £1,992 to
£19,609)
1.6593
(95% CI 0.5832 to
3.3798)
£25,505.80
(95% CI £1,077.92 to
£60,880.86)
£42,098.73
(95% CI £8,084.29 to
£94,081.58)
Open distal pancreatectomy £8,321
(95% CI £1,410 to
£22,374)
1.5059
(95% CI 0.5316 to
3.0695)
£21,797.22
(95% CI -£2,999.81 to
£54,686.77)
£36,856.49
(95% CI £3,931.88 to
£84,698.84)
Incremental -£641
(95% CI -£12075 to
£12214)
0.1534
(95% CI -0.0042 to
0.4261)
£3,708.58
(95% CI -£9,473.62 to
£16,115.69)
£5,242.23
(95% CI -£8,443.26 to
£18,761.80)
* Calculated at willingness to pay thresholds of £20,000 and £30,000 per QALY gained.
QALY = quality adjusted life year.
https://doi.org/10.1371/journal.pone.0189631.t004
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Scenario analysis 2: Difference in the health-related quality of life between laparoscopic
and open distal pancreatectomy. As indicated in Table 5, there was no change in the inter-
pretation of the results compared to the main analysis.
Discussion
Summary of findings
This cost-utility analysis showed that laparoscopic distal pancreatectomy resulted in decreased
costs compared to open distal pancreatectomy and resulted in a small increase in QALY (0.15
QALY per patient). Therefore, laparoscopic distal pancreatectomy dominated open distal pan-
createctomy. However, the confidence intervals of NMB overlapped zero, i.e. there was uncer-
tainty about the cost-effectiveness of laparoscopic distal pancreatectomy compared to open
distal pancreatectomy. The probability of laparoscopic distal pancreatectomy being cost-effec-
tive compared to open distal pancreatectomy was 70% to 80% for at the willingness-to-pay
thresholds generally used in England (£20,000 to £30,000 per QALY gained).
Limitations of the analysis
The major limitation of this analysis is the lack of data. The information used is from observa-
tional studies and not from randomised controlled trials. Because of this there are concerns
about whether the estimates of laparoscopic distal pancreatectomy versus open distal pancrea-
tectomy obtained in observational studies are reliable [11]. In fact, in the Cochrane review, it
was noted that there was a high likelihood that patients with more advanced disease had open
distal pancreatectomy and those with less advanced disease underwent laparoscopic distal pan-
createctomy [11]. Thus, there is concern about the safety and oncological clearance offered by
laparoscopic distal pancreatectomy for resections requiring resection of adjacent structures
such as blood vessels.
There is currently no information on the health-related quality of life (reported as prefer-
ence-based measures such as EQ-5D) after uncomplicated or complicated laparoscopic distal
pancreatectomy and complicated open distal pancreatectomy. Health-related quality of life
(reported as preference-based measures such as EQ-5D) was available in two studies of small
sample sizes which did not relate to laparoscopic or open distal pancreatectomy. These studies
which were not powered to identify differences in health-related quality of life between com-
plicated and uncomplicated liver resection or gynaecological surgery [15, 16]. However, this is
counterintuitive and therefore, we used a hypothetical 20% relative decrease in short-term
Table 5. Results of probabilistic sensitivity analysis (per patient) (scenario analysis 2).
Treatment Costs QALYs Net monetary benefit*
£20,000 £30,000
Laparoscopic distal
pancreatectomy
£7,719
(95% CI £1,927 to
£20,261)
1.6498
(95% CI 0.5955 to
3.3128)
£25277.36
(95% CI £1489.24 to
£58981.13)
£41775.39
(95% CI £8808.85 to
£91765.32)
Open distal pancreatectomy £8,574
(95% CI £1,631 to
£21,802)
1.5116
(95% CI 0.5539 to
2.9985)
£21658.93
(95% CI -£1351.14 to
£53308.83)
£36775.18
(95% CI £5280.99 to
£83402.58)
Incremental -£855
(95% CI -£12312 to
£12176)
0.1382
(95% CI -0.0111 to
0.3989)
£3618.43
(95% CI -£9796.78 to
£16258.35)
£5000.22
(95% CI -£8860.85 to
£18803.70)
* Calculated at willingness to pay thresholds of £20,000 and £30,000 per QALY gained.
QALY = quality adjusted life year.
https://doi.org/10.1371/journal.pone.0189631.t005
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HRQoL because of surgical complications based on the opinion of clinical experts. We also
used a hypothetical 10% relative increase in short-term HRQoL because of laparoscopic distal
pancreatectomy compared to open distal pancreatectomy. The cost-effectiveness was not sen-
sitive to changes in the relative decrease in the HRQoL due to complications and increase in
the HRQoL because of the use of laparoscopy.
The complication rates in people who underwent laparoscopic distal pancreatectomy were
based on information from a Cochrane review involving observational studies in which people
with more extensive cancer received open distal pancreatectomy more often and people with
less extensive cancer received laparoscopic distal pancreatectomy more often [11]. Therefore,
there is a high risk of systematic error (bias) favouring laparoscopic distal pancreatectomy.
The number of participants included in the studies that contributed data for this review was
small and the studies were not powered to measure differences in harms. Thus, there is high
risk of random error. In addition, it is unlikely that major complications related to laparo-
scopic distal pancreatectomy are reported in the literature because of the lack of incentive to
publish these; so, there may be publication bias. Formal audits of laparoscopic distal pancrea-
tectomy are necessary to ensure that complications related to laparoscopic distal pancreatec-
tomy are recorded and are comparable with open distal pancreatectomy. Because of the above
limitations in data, the results may change when better data becomes available.
Applicability of findings of the research
Studies included only patients with pancreatic cancer who were eligible for surgery. So, the find-
ings of the review are applicable only in distal pancreatectomy performed in patients with pan-
creatic cancer who were eligible for surgery. The costs were based on NHS reference costs and
the cost-effectiveness analysis used a willingness-to-pay threshold in UK. Therefore, the results
are applicable in the NHS setting and other settings with similar methods of reimbursement.
Comparisons with previous research
This is the first cost-utility analysis on laparoscopic distal pancreatectomy versus open distal
pancreatectomy specifically for pancreatic cancer. We identified one cost-utility analysis of
laparoscopic distal pancreatectomy versus open distal pancreatectomy for benign and malig-
nant pancreatic lesions in the body or tail of the pancreas, which revealed that laparoscopic
distal pancreatectomy was cost-effective to open distal pancreatectomy if the willingness-to-
pay threshold was €5400 per QALY, i.e. laparoscopic distal pancreatic was cost-effective com-
pared to open distal pancreatectomy in the NHS setting [19].
Further research
Further research to collect data on costs, utilities, and probabilities associated with laparo-
scopic versus open distal pancreatectomy are required, particularly in relation to oncological
efficacy of the laparoscopic procedure, survival probabilities, incidence of complications, and
the utilities related to complicated and uncomplicated distal pancreatectomy. These should be
collected from randomised controlled trials as randomisation is the only way to ensure that
similar types of participants underwent laparoscopic distal pancreatectomy and open distal
pancreatectomy.
Conclusions
It appears that there is uncertainty about whether laparoscopic distal pancreatectomy is cost-
effective compared to open distal pancreatectomy for pancreatic cancer in the NHS setting.
Cost-effectiveness of laparoscopic versus open distal pancreatectomy for pancreatic cancer
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However, because of the limitations in the available data, the results may change when better
data becomes available.
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